Most preclinical neuroscience programs are still built around two categories of evidence. Behavior tells you what the animal does, and histology...
Histology has always carried a quiet tension. It is the most direct evidence a preclinical study can offer, a look at the actual tissue the candidate...
Remyelination has become the most interesting frontier in multiple sclerosis. The approved therapies for relapsing disease are effective at...
AAALAC accreditation carries practical weight in preclinical drug development, and its implications for program quality extend beyond the credential...
Botulinum toxin type A has been established as a therapeutic agent in spasticity, dystonia, and cosmetic indications for several decades. Its...
Spinal cord injury presents one of the most challenging translational profiles in central nervous system drug development. The clinical need is...
The challenge in translational research is not generating data but generating actionable confidence.
Pain and wound healing research demand models that accurately reflect human tissue structure, innervation, and functional recovery. While rodents...
Drug development rarely fails because a compound lacked activity. More often, it fails because preclinical models failed to predict clinical reality.
